<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MYAMBUTOL- ethambutol hydrochloride tablet </strong><br>Cardinal Health<br></p></div>
<h1>Myambutol<span class="Sup">®</span> Ethambutol Hydrochloride Tablets, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d24b0a65-26eb-4385-887c-dce5c2e0d18f"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">MYAMBUTOL<span class="Sup">®</span> ethambutol hydrochloride is an oral chemotherapeutic agent which is specially effective against actively growing microorganisms of the genus Mycobacterium, including <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>.  The structural formula is:</p>
<div class="Figure">
<a name="id258"></a><img alt="formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92e486cf-3a07-4178-b4df-52226e0401e1&amp;name=image-01.jpg">
</div>
<p>MYAMBUTOL<span class="Sup">®</span> 100 and 400 mg tablets contain the following inactive ingredients: Gelatin, Hydroxypropyl Methycellulose, Magnesium Stearate, Sodium Lauryl Sulfate, Sorbitol, Stearic Acid, Sucrose, Titanium Dioxide and other ingredients.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_b500a0f8-047e-4e36-b39b-69623e93e3da"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">MYAMBUTOL<span class="Sup">®</span> following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/mL in serum 2 to 4 hours after administration.  When the drug is administered daily for longer periods of time at this dose, serum levels are similar.  The serum levels of MYAMBUTOL <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> to undetectable levels by 24 hours after the last dose except in some patients with abnormal renal function.  The intracellular concentrations of erythrocytes reach peak values approximately twice those of plasma and maintain this ratio throughout the 24 hours.</p>
<p>During the 24-hour period following oral administration of MYAMBUTOL approximately 50 percent of the initial dose is excreted unchanged in the urine, while an additional 8 to 15 percent appears in the form of metabolites.  The main path of metabolism appears to  be an initial oxidation of the alcohol to an aldehydic intermediate, followed by conversion to a dicarboxylic acid.  From 20 to 22 percent of the initial dose is excreted in the feces as unchanged drug.  No drug accumulation has been observed with consecutive single daily doses of 25 mg/kg in patients with normal kidney function, although marked accumulation has been demonstrated in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>MYAMBUTOL diffuses into actively growing <span class="Italics">mycobacterium</span> cells such as tubercle bacilli.  MYAMBUTOL appears to inhibit the synthesis of one or more metabolites, thus causing impairment of cell metabolism, arrest of multiplication, and <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>.  No cross resistance with other available antimycobacterial agents has been demonstrated.</p>
<p>MYAMBUTOL has been shown to be effective against <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> but does not seem to be active against fungi, viruses, or other bacteria.  <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> previously unexposed to MYAMBUTOL have been uniformly sensitive to concentrations of 8 or less mcg/mL, depending on the nature of the culture media.  When MYAMBUTOL has been used alone for treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, tubercle bacilli from these patients have developed resistance of MYAMBUTOL ethambutol hydrochloride by in vitro susceptibility tests; the development of resistance has been unpredictable and appears to occur in a step-like manner.  No cross resistance between MYAMBUTOL and other antituberculous drugs has been reported.  MYAMBUTOL has reduced the emergence of mycobacterial resistance is isoniazid when both drugs have been used concurrently.</p>
<p>Any agar diffusion microbiologic assay, based upon inhibition of <span class="Italics">Mycobacterium smegmatis</span> (ATCC 607) may be used to determine concentrations of MYAMBUTOL in serum and urine.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_f332f8ce-90cc-470d-bbed-770742049d85"></a><a name="section-3"></a><p></p>
<h1>ANIMAL PHARMACOLOGY</h1>
<p class="First">Toxicological studies in dogs on high prolonged doses produced evidence of myocardial damage and failure, and depigmentation of the tapetum lucidum of he eyes, the significance of which is not known.  Degenerative changes in the central nervous system, apparently not dose-related, have also been noted in dogs receiving ethambutol hydrochloride over a prolonged period.</p>
<p>In the rhesus monkey, neurological signs appeared after treatment with high doses given daily over a period of several months.  These were correlated with specific serum levels of ethambutol hydrochloride and with definite neuroanatomical changes in the central nervous system.  Focal interstitial carditis was also noted in monkeys which received ethambutol hydrochloride in high doses for a prolonged period.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_d5c196aa-200f-48c0-9f84-aea96728c89f"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">MYAMBUTOL is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span>.  It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug.  Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies.  In patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following:</p>
<p>MYAMBUTOL plus isoniazid</p>
<p>MYAMBUTOL plus isoniazid plus streptomycin</p>
<p>In patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent.  Consequently, in such retreatment patients, MYAMBUTOL should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies.  Antituberculous drugs used with MYAMBUTOL have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs.  Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens.  Alternating drug regimens have also been utilized.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_7f9cc8f9-dd4b-4894-b146-14a1e12617e1"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">MYAMBUTOL is contraindicated in patients who are known to be hypersensitive to this drug.  It is also contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> unless clinical judgement determines that it may be used.  MYAMBUTOL is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> patients).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_378276f6-38bd-4824-a8d0-5a41f19a5ace"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">MYAMBUTOL may produce decreases in visual acuity which appear to be due to <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>.  This effect may be related to dose and duration of treatment.  This effect is generally reversible when administration of the drug is discontinued promptly.  However, irreversible <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> has been reported.  (See PRECAUTIONS and ADVERSE REACTIONS).</p>
<p>liver toxicities including fatalities have been reported (see ADVERSE REACTIONS).  Baseline and periodic assessment of hepatic function should be performed.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_bf219ba2-3713-4e3d-8d7e-c57d559ade9c"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">MYAMBUTOL ethambutol hydrochloride is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established.</p>
<p>Patients with decreased renal function need the dosage reduced as determined by serum levels of MYAMBUTOL, since the main path of excretion of this drug is by the kidneys.</p>
<p>Because this drug may have adverse effects on vision, physical examination should include ophthalmoscopy, finger perimetry and testing of color discrimination.  In patients with visual defects such as <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, recurrent inflammatory conditions of the eye, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, and <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>, the evaluation of changes in visual acuity is more difficult, and care should be taken to be sure the variations in vision are not due to the underlying disease conditions.  In such patients, consideration should be given to relationship between benefits expected and possible visual deterioration since evaluation of visual changes is difficult.  (For recommended procedures, see next paragraphs under ADVERSE REACTIONS.)</p>
<p>As with any potent drug, baseline and periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, should be performed.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_529b8d86-a953-4434-8893-a99e5270b8a9"></a><a name="section-7.1"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.  It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_dee0092e-696c-4437-a822-60d3f63177e5"></a><a name="section-7.2"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_95d7d420-72a0-4841-a7c8-e03de801b81a"></a><a name="section-7.2.1"></a><p></p>
<h3>Teratogenic Effects: Pregnancy Category C.</h3>
<p class="First">There are no adequate and well-controlled studies in pregnant women.  There are reports of ophthalmic abnormalities occuring in infants born to women on antituberculous therapy that included ethambutol hydrochloride.  MYAMBUTOL should be used during pregnancy only if the benefit justifies the potential risk to the fetus.</p>
<p>MYAMBUTOL has been shown to be teratogenic in pregnant mice and rabbits when given in high doses.  When pregnant mice or rabbits were treated with high doses of ethambutol hydrochloride, fettal mortality was slightly but not significantly (P&gt;0.05) increased.  Femal rats treated with ethambutol hydrochloride displayed slight but insignificant (P&gt;0.05) decreases in fertility and litter size.</p>
<p>In fetuses born of mice treated with high doses of MYAMBUTOL during pregnancy, a low incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span> and abnormality of the vertebral column were observed.  Minor abnormalities of the cervical vertebra were seen in the newborn of rats treated with high doses of ethambutol hydrochloride during pregnancy.  Rabbits receiving high doses of MYAMBUTOL during pregnancy gave birth to two fetuses with monophthalmmia, one with a shortened right forearm accompanied by bulateral wrist-<span class="product-label-link" type="condition" conceptid="73290" conceptname="Contracture of joint">joint contracture</span> and one with <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">hare lip</span> and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_329e879a-40b8-49b4-a6b2-1663a93949ae"></a><a name="section-7.3"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">MYAMBUTOL is excreted into breast milk.  The use of MYAMBUTOL should be considered only if the expected benefit to the mother outweighs the potential risk to the infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_381a1a55-10f9-4cda-a490-c91c7016c69b"></a><a name="section-7.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">MYAMBUTOL ethambutol hydrochloride is not recommended for use in pediatric patients under thirteen years of age since safe conditions have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_ba910111-4376-4fb4-b2ec-722a3e306cfe"></a><a name="section-7.5"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">There are limited date on the use of ethambutol in the elderly.  One study of 101 patients, 65 years and older, on multiple drug antituberculosis regimens included 94 patients on ethambutol.  No differences in safety of tolerability were observed in these patients compared with that reported in adults in general.</p>
<p>Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_9a5f559f-7978-48ee-b04e-f138ac895e4a"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">MYAMBUTOL may produce decreases in visual acuity, including irreversable <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, which appear o be due to <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>.  <span class="product-label-link" type="condition" conceptid="380410" conceptname="Nutritional optic neuropathy">Optic neuropathy</span> including <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> or <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">retrobulbar neuritis</span> occuring in association with ethambutol therapy may be characterized by one or more of the following events: decreased visual acuity, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>, <span class="product-label-link" type="condition" conceptid="372633" conceptname="Deutan defect">color blindness</span>, and/or visual defect.  These events have also been reported in the absence of a diagnosis of optic or <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">retrobulbar neuritis</span>.</p>
<p>Patients should be advised to report promptly to their physician any change of visual acuity</p>
<p>The change in visual acuity may be unilateral or bilateral and hence <span class="Italics">each eye must be tested separately and both eyes tested together</span>.  Testing of visual acuity should be performed before beginning MYAMBUTOL therapy and periodically during drug administration, except that it should be done monthly when a patient is on a dosage of more than 15 mg per kilogram per day.  Snellen eye charts are recommeneded for testing of visual acuity.  Studies have shown that there are definite fluctuations of one or two lines of the Snellen chart in the visual acuity of many tuberculous patients <span class="Italics">not</span> receiving MYAMBUTOL.</p>
<p>The following table may be useful in interpreting possible changes in visual acuity attributable to MYAMBUTOL.</p>
<table width="100%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Initial Snellen Reading</p></td>
<td class="Botrule Lrule Toprule"><p class="First">Reading Indicating Significant Decrease</p></td>
<td class="Botrule Lrule Toprule"><p class="First">Significant Number of Lines</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Decrease Number of Points</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">20/13</p></td>
<td class="Botrule Lrule"><p class="First">20/25</p></td>
<td class="Botrule Lrule"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">20/15</p></td>
<td class="Botrule Lrule"><p class="First">20/25</p></td>
<td class="Botrule Lrule"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">20/20</p></td>
<td class="Botrule Lrule"><p class="First">20/30</p></td>
<td class="Botrule Lrule"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">20/25</p></td>
<td class="Botrule Lrule"><p class="First">20/40</p></td>
<td class="Botrule Lrule"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule"><p class="First">15</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">20/30</p></td>
<td class="Botrule Lrule"><p class="First">20/50</p></td>
<td class="Botrule Lrule"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">20/40</p></td>
<td class="Botrule Lrule"><p class="First">20/70</p></td>
<td class="Botrule Lrule"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule"><p class="First">30</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">20/50</p></td>
<td class="Botrule Lrule"><p class="First">20/70</p></td>
<td class="Botrule Lrule"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule"><p class="First">20</p></td>
</tr>
</tbody>
</table>
<p>In general, changes in visual acuity less than those indicated under "Significant Number of Lines" and "Decrease Number of Points" may be due to chance variation, limitations of the testing method, or physiologic variability.  Conversely, changes in visual acuity equaling or exceeding those under "Significant Number of LInes" and "Decrease Number of Points" indicate need for retesting and careful evaluation of the patient's visual status.  If careful evaluation confirms the magnitude of visual change and fails to reveal another cause, MYAMBUTOL should be discontinued and the patient reevaluated at frequent intervals.  Progressive decreases in visual acuity during therapy must be considered to be due to MYAMBUTOL.</p>
<p>If corrective glasses are used prior to treatment, these must be worn during visual acuity testing.  During 1 to 2 years of therapy, a refractive error may develop which must be corrected in order to obtain accurate test results.  Testing the visual acuity through a pinhole eliminates refractive error.  Patients developing visual abnormality during MYAMBUTOL treatment may show subjective visual symptoms before, or simultaneously with, the demonstration of decreases in visual acuity, and all patients receiving MYAMBUTOL should be questioned periodically about <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and other subjective eye symptoms.</p>
<p>Recovery of visual acuity generally occurs over a period of weeks to months after the drug has been discontinued.  Some patients have received MYAMBUTOL ethambutol hydrochloride again after such recovery without recurrence of loss of visual acuity.</p>
<p>Other adverse reactions reported include: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, erythmea multiforme, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>; <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and possible <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the extremities due to <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span> have been reported.</p>
<p>Elevated serum uric acid levels occur and precipiation of acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> has been reported.  Pulmonary infiltrates, with or without <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, also have been reported during MYAMBUTOL therapy.  Liver toxicities, including fatalities, have been reported.  (See WARNINGS).  Since MYAMBUTOL is recommended for therapy in conjunction with one or more other antituberculous drugs, these changes may be related to the concurent therapy.  <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">Hypersensitivity syndrome</span> consisting of cutaneous reaction (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or exofoliative <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>), <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and one or more of the following: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>.  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> may be present.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a690c9a9-caf3-4fb9-afa2-7dc7be806d79"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">MYAMBUTOL should not be used alone, in initial treatment or in retreatment.  MYAMBUTOL should be administered on a once every 24-hour basis only.  Absorption is not significantly altered by administration with food.  Therapy, in general, should be continued until bacteriological conversion has become permanent and maximal clinical improvement has occured.  </p>
<p>MYAMBUTOL is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established.</p>
<p><span class="Bold">Initial Treatment</span>: In patients who have not received previous antituberculous therapy, administer MYAMBUTOL 15 mg/kg (7 mg/lb) of body weight, as a single oral dose once every 24 hours.  In the more recent studies, isoniazid has been administered concurrently in a single, daily, oral dose.</p>
<p>Retreatment: In patients who have received previous antituberculous therapy, administer MYAMBUTOL 25 mg/kg (11mg/lb) of body weight, as a single oral dose once every 24 hours.  Concurrently administer at least one other antituberculous drug to which the organisms have been demonstrated to be susceptible by appropriate in vitro tests.  Suitable drugs usually consist of those not previously used in the treatment of the patient.  After 60 days of MYAMBUTOL administration, decrease the dose to 15 mg/kg (7 mg/lb) of body weight, and administer as a single oral dose once every 24 hours.</p>
<p>During the period when patient is on a daily dose of 25 mg/kg, monthly eye examinations are advised.</p>
<p>See Table for easy selection of proper weight-dose tablet(s).</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First"><span class="Bold">Weight-Dose Table 15 mg/kg (7 mg/lb) Schedule</span></p></td></tr>
<tr>
<td class="Botrule Lrule" colspan="2"><p class="First"><span class="Bold">Weight Range</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Daily Dose</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Pounds</span></p></td>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Kilograms</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">In mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Under 85 lbs</p></td>
<td class="Botrule Lrule"><p class="First">Under 37 kg</p></td>
<td class="Botrule Lrule Rrule"><p class="First">500</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">85-94.5</p></td>
<td class="Botrule Lrule"><p class="First">37-43</p></td>
<td class="Botrule Lrule Rrule"><p class="First">600</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">95-109.5</p></td>
<td class="Botrule Lrule"><p class="First">43-50</p></td>
<td class="Botrule Lrule Rrule"><p class="First">700</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">110-124.5</p></td>
<td class="Botrule Lrule"><p class="First">50-57</p></td>
<td class="Botrule Lrule Rrule"><p class="First">800</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">125-139.5</p></td>
<td class="Botrule Lrule"><p class="First">57-64</p></td>
<td class="Botrule Lrule Rrule"><p class="First">900</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">140-154.5</p></td>
<td class="Botrule Lrule"><p class="First">64-71</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1000</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">155-169.5</p></td>
<td class="Botrule Lrule"><p class="First">71-79</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1100</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">170-184.5</p></td>
<td class="Botrule Lrule"><p class="First">79-84</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1200</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">185-199.5</p></td>
<td class="Botrule Lrule"><p class="First">84-90</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1300</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">200-214.5</p></td>
<td class="Botrule Lrule"><p class="First">90-97</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1400</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">215 and Over</p></td>
<td class="Botrule Lrule"><p class="First">Over 97</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1500</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">25 mg/kg (11 mg/lb) Schedule</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Under 85 lbs</p></td>
<td class="Botrule Lrule"><p class="First">Under 38 kg</p></td>
<td class="Botrule Lrule Rrule"><p class="First">900</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">85-92.5</p></td>
<td class="Botrule Lrule"><p class="First">38-42</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1000</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">93-101.5</p></td>
<td class="Botrule Lrule"><p class="First">42-45.5</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1100</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">102-109.5</p></td>
<td class="Botrule Lrule"><p class="First">45.5-50</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1200</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">110-118.5</p></td>
<td class="Botrule Lrule"><p class="First">50-54</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1300</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">119-128.5</p></td>
<td class="Botrule Lrule"><p class="First">54-58</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1400</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">129-136.5</p></td>
<td class="Botrule Lrule"><p class="First">58-62</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1500</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">137-146.5</p></td>
<td class="Botrule Lrule"><p class="First">62-67</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1600</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">147-155.5</p></td>
<td class="Botrule Lrule"><p class="First">67-71</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1700</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">156-164.5</p></td>
<td class="Botrule Lrule"><p class="First">71-75</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1800</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">165-173.5</p></td>
<td class="Botrule Lrule"><p class="First">75-79</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1900</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">174-182.5</p></td>
<td class="Botrule Lrule"><p class="First">79-83</p></td>
<td class="Botrule Lrule Rrule"><p class="First">2000</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">183-191.5</p></td>
<td class="Botrule Lrule"><p class="First">83-87</p></td>
<td class="Botrule Lrule Rrule"><p class="First">2100</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">192-199.5</p></td>
<td class="Botrule Lrule"><p class="First">87-91</p></td>
<td class="Botrule Lrule Rrule"><p class="First">2200</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">200-209.5</p></td>
<td class="Botrule Lrule"><p class="First">91-95</p></td>
<td class="Botrule Lrule Rrule"><p class="First">2300</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">210-218.5</p></td>
<td class="Botrule Lrule"><p class="First">95-99</p></td>
<td class="Botrule Lrule Rrule"><p class="First">2400</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">219 and Over</p></td>
<td class="Botrule Lrule"><p class="First">Over 99</p></td>
<td class="Botrule Lrule Rrule"><p class="First">2500</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_07744c8b-3e48-4e7d-8ebd-c6b6b4918a45"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MYAMBUTOL<span class="Sup">®</span> Ethambutol Hydrochloride Tablets USP</p>
<p>100 mg - round, convex, white, film coated tablets engraved M6 on one side are supplied as follows:</p>
<p>NDC 68850-010-01 - Bottle of 100</p>
<p>400 mg - round, convex, white, scored, film coated tablets engraved with M to the left and 7 to the right of the score on one side are supplied as follows:</p>
<p>NDC 68850-012-01 - Bottle of 100</p>
<p>NDC 68850-012-02 - 10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span>-packs x 10 Tablets</p>
<p><span class="Bold">Store at controlled room temperature 20° to 25°C (68° to 77°F).</span></p>
<p>Manufactured by: Patheon, Inc., Ontario, Canada</p>
<p>For STI Pharma LLC.</p>
<p>Distributed by: X-GEN Pharmaceuticals Inc., </p>
<p>Big Flats, NY 14814</p>
<p>Myambutol is a registered trademark of STI Pharma LLC.</p>
<p>© 2008 STI Pharma LLC.</p>
<p>Revised November 2008</p>
<p>MY012-02-2</p>
<p>2551-25-08A</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4d82767e-d718-4f6b-8a9c-944fd28b13b5"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Myambutol<span class="Sup">®</span> Tablets USP 400 mg</p>
<p>Ethambutol Hydrochloride</p>
<p>10 Tablets</p>
<div class="Figure">
<a name="id-2063780118"></a><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92e486cf-3a07-4178-b4df-52226e0401e1&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MYAMBUTOL 		
					</strong><br><span class="contentTableReg">ethambutol hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-4550(NDC:68850-012)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ETHAMBUTOL HYDROCHLORIDE</strong> (ETHAMBUTOL) </td>
<td class="formItem">ETHAMBUTOL HYDROCHLORIDE</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (convex) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;7</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-4550-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016320</td>
<td class="formItem">06/27/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-4550)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4d47d787-4cfd-4b2e-ba08-452168eff880</div>
<div>Set id: 92e486cf-3a07-4178-b4df-52226e0401e1</div>
<div>Version: 2</div>
<div>Effective Time: 20141208</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
